Immunoinformatics based designing a multi‐epitope vaccine against pathogenic <i>Chandipura vesiculovirus</i>

Deb, Debashrito; Basak, Srijita; Kar, Tamalika; Narsaria, Utkarsh; Castiglione, Filippo; Paul, Abhirup; Pandey, Ashutosh; Srivastava, Anurag P.

doi:10.1002/jcb.30170

Cited by 5 publications

(1 citation statement)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various studies have been conducted using similar immunoinformatics protocols to develop MEVs against various human diseases. This includes and is not limited to Chandipura vesiculovirus (CHPV) ( 119 ), malaria ( 57 ), cutaneous leishmaniasis ( 120 ), tuberculosis ( 121 ) and SARS Coronavirus-2 (SARS-CoV-2) ( 122 ). Two in-silico studies have been carried out for BU ( 33 , 34 ).…”

Section: Discussionmentioning

confidence: 99%

Identification of potential candidate vaccines against Mycobacterium ulcerans based on the major facilitator superfamily transporter protein

et al. 2022

View full text Add to dashboard Cite

Buruli ulcer is a neglected tropical disease that is characterized by non-fatal lesion development. The causative agent is Mycobacterium ulcerans (M. ulcerans). There are no known vectors or transmission methods, preventing the development of control methods. There are effective diagnostic techniques and treatment routines; however, several socioeconomic factors may limit patients’ abilities to receive these treatments. The Bacillus Calmette–Guérin vaccine developed against tuberculosis has shown limited efficacy, and no conventionally designed vaccines have passed clinical trials. This study aimed to generate a multi-epitope vaccine against M. ulcerans from the major facilitator superfamily transporter protein using an immunoinformatics approach. Twelve M. ulcerans genome assemblies were analyzed, resulting in the identification of 11 CD8+ and 7 CD4+ T-cell epitopes and 2 B-cell epitopes. These conserved epitopes were computationally predicted to be antigenic, immunogenic, non-allergenic, and non-toxic. The CD4+ T-cell epitopes were capable of inducing interferon-gamma and interleukin-4. They successfully bound to their respective human leukocyte antigens alleles in in silico docking studies. The expected global population coverage of the T-cell epitopes and their restricted human leukocyte antigens alleles was 99.90%. The population coverage of endemic regions ranged from 99.99% (Papua New Guinea) to 21.81% (Liberia). Two vaccine constructs were generated using the Toll-like receptors 2 and 4 agonists, LprG and RpfE, respectively. Both constructs were antigenic, non-allergenic, non-toxic, thermostable, basic, and hydrophilic. The DNA sequences of the vaccine constructs underwent optimization and were successfully in-silico cloned with the pET-28a(+) plasmid. The vaccine constructs were successfully docked to their respective toll-like receptors. Molecular dynamics simulations were carried out to analyze the binding interactions within the complex. The generated binding energies indicate the stability of both complexes. The constructs generated in this study display severable favorable properties, with construct one displaying a greater range of favorable properties. However, further analysis and laboratory validation are required.

show abstract